Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APG279
- Development stage
- Phase 1
- Lead developer
- Apogee Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
**APG279** is an investigational fixed-dose, coformulated combination of two half-life-extended monoclonal antibodies: zumilokibart (APG777), which neutralizes interleukin-13, and APG990, which blocks OX40 ligand. The combination is designed to concurrently inhibit IL-13-driven Type 2 inflammation and OX40L-mediated immune activation across Type 1, Type 2, and Type 3 inflammatory pathways. It is being developed by Apogee Therapeutics as a subcutaneous treatment for adults with moderate-to-severe atopic dermatitis and is being evaluated against dupilumab in a Phase 1b study. ([apogeetherapeutics.com](https://www.apogeetherapeutics.com/pipeline))
- Other names
- APG777 + APG990zumilokibart + APG990
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)TNFSF4 (Tumor necrosis factor ligand superfamily member 4)IL-13 (Interleukin-13)
Beyond the preview
Go deeper on APG279.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APG279.